• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Heparin is extracted from intestinal brine, i.e., from the brine which results from the preservation and dewatering treatment of animal tissue with sodium chloride, using conventional methods. The extracted product has a high activity and can subsequently be further purified to yield very high heparin activities.
    公开号:SU1028237A3
    申请号:SU772531003
    申请日:1977-10-19
    公开日:1983-07-07
    发明作者:Видик Ханс-Ерг
    申请人:Шеринг Аг (Фирма)；
    IPC主号:
    专利说明:

    one§
    This invention relates to the medicine industry and concerns the manufacture of heparin, which is used in medicine as an anticoagulant agent.
    A known method for producing gerarin by treating an animal stock with a solution of sodium chloride followed by its isolation in a known way {1.
    However, the known method is time consuming, long and does not provide high purity of the target product.
    The purpose of the invention is to increase the purity of the target product and simplify the method.
    The goal is achieved by the fact that when carrying out the method of producing heparin by treating animal raw material with a solution of sodium chloride followed by its isolation with a known rut, the raw material is gut-free gut and the treatment is carried out with solid sodium chloride or its solution in a neutral medium at 1–25 s.
    For the purpose of preserving and dehydrating the intestines of animals, batch solutions are especially suitable. A salt containing from 0.5 MG to the number of moles of saturation is preferably from 3 mol to the number of moles of saturation. By the number of moles of saturation is meant the number of moles which contains a concentrated aqueous solution at room temperature (cutting at the slaughterhouse) of dissolved salt. Concentrated aqueous solution of table salt is about 26.4%. It is obtained by sprinkling the intestines of animals with table salt.
    After removing mucus, the animals' guts are treated for 2 to 3 days with sodium chloride solutions. In most cases, the treatment of animal intestines is completed within 3–24 hours. After removing the preserved and dehydrated animal intestines from the salt solution, I receive intestinal brine, which has a high heparin content.
    ,Example. 1. In a 1500-liter blender, stir 600 liters of brine with 600 liters of methanol for half an hour at room temperature. Then stirring is continued for another half hour and left for 1 hour. Then the upper liquid is decanted into the second vessel and the salt is allowed to settle. The resulting suspension is left for 2 days. After that, it is decanted again, the upper liquid is taken up and the precipitate is separated by centrifugation. After drying in vacuum, 1.68 kg of product is obtained, I have:
    11 USP-U / mg. It contains about 60% of table salt.
    Example 2. 3 l of brine is acidified with stirring with acetic acid to pH 3.1-3.2 (about 50 ml. After several hours, the solution is decanted and the residue is centrifuged. The precipitate is discarded and the purified solutions are neutralized with sodium hydroxide and then slowly with stirring, mixed with the precipitated sodium chloride. This suspension is left to stand for several hours, the upper liquid is decanted, and the precipitate is centrifuged. The precipitate is dried under vacuum and 3.76 g of product with an activity of 23 USP units / mg is obtained.
    Example 3.3 l of brine is diluted with 14 l of water. Then, 50 g of kieselguhr and a solution of 7 g of non-nonium chloride in 100 ml of water are added. After a few hours, the liquid is decanted and the residue is filtered off with suction. After washing with water, the still wet precipitate is extracted three times with 200 ml of 2 M sodium chloride solution. The combined sediment extracts, tsayut 2 ob.h. methanol. The isolated and dried edema weighs 560 mg and has an activity of 163 R-units / mg.
    Example 4. 3 l of brine is adjusted to pH 3.1-3.2 by adding acetic acid with stirring. After a few hours, the solution is decanted and the residue is centrifuged. The combined solutions are diluted with water to 15.5 liters and 40 g of diatomaceous earth and 7 g of benzenethium chloride are added. After a few hours the precipitate; isolated as in example 3 and pererabot: bathed on. 796 ml of product with an activity of 105: 10 mg units / mg are obtained.
    EXAMPLE 5: 3 -l brine is diluted with 13 liters of water. Then the solution
    : acidified with acetic acid to
    pH 3.2 (about 50 ml). After a few hours, a precipitate is released, which after decanting the clear liquid is centrifuged. After drying, 16.6 g of crude heparin with an activity of 5.5 and 5P - units / mg are obtained.
    Example 6 10 L brine was diluted with 50 L water. Egutvor is passed with the help of Hacocci through a filter in the form of an ion exchange column with a diameter of 26 and a length of 380 mm (about 3 l / h). Medium ionic microporous ion-exchange is used in the chlorinated form (CA 9249 levatit). Other anion exchange resins, such as Dowex 1-X-1 resin, may also be used.
    The resin was then removed from the column, washed 2 times with 500 ml of a 0.9 M sodium chloride solution, and zyuyvayut 400 ml of 2 M sodium chloride solution for 5 h with stirring. This solution is precipitated for 1.5 hours the volume of methanol. The isolated and dried sediment weighs 1.5 g and has an activity of 152 USP-u / mg. Example 7. An aliquot of uncleaned heparin from example 1, with an activity of 425 OOUSP | s / mg or 38.65 g, was extracted 3 times with 200 ml of 2 M sodium chloride solution, each time t being reduced to 60 s. The combined extracts are diluted with water to a chlorine content of 0.9 mol / L in solution. Then, 200 ml of anion exchange resin Levatat CA 9249 in chlorinated form is added and mixed for 1 h. The resin is sucked off and washed with 200 ml of a 0.9 M solution of the salt. After this, the ion exchange resin is eluted for 5 hours with a 2 M solution of sodium chloride at, sucked off and washed with a 2 M solution of sodium chloride. The eluted solution is combined with the wash solution and precipitated with 1.5 volumes of methanol. The precipitate is centrifuged, first washed with 50 m aqueous methanol (1: 1.5 by volume) and 1.91 g of sodium geiarinate with an activity of 102 USP-units / mg is obtained. Example 8. 15 g of heparinate obtained in accordance with Example 7 with an activity of 200 FG-units / mg were dissolved in 200 ml of a 2 M solution of renal salt. The solution is filtered off with suction and the residue is first washed with 30 ml of 2m solution of boiling water and then with 250 ml of completely desalinated water. The combined solutions with completely desalted water are brought to molar and 0.9 molar (chloride. | I6). Then, analogously to example 7, the purification is repeated with 1 l of levatite CA 9249. The combined eluate and the washing solution are processed as indicated. After washing and drying the precipitate, it is obtained 11.1 g sodium heparinate with an activity of 254 USP-units / mg. Example 9. 600 liters of brine are treated with 600 liters of methanol in a stirred reactor with a capacity of 1500 liters with stirring at room temperature for half an hour. The mixture is stirred for an additional half hour, after which the mixture is kept for about 1 hour. The upper turbid layer is decanted into the second tank and the precipitated salt residue is drained back. The resulting suspension was incubated for two days. It is then decanted again, the sludge is discarded, and the residue is separated by centrifugal extraction. After drying under vacuum, 1.44 M kg of product is obtained, which has an activity of about 10 IIJSP-U / mg. The product also contains about 45% of common salt. The amount of crude heparin thus obtained (fcooTBCTCTBeH oyolo 425000 lUSP-eaten 42.5 g) was extracted three times, each time used 200 ml of 2 M sodium chloride solution, and stirred as needed for 1 h, at. The combined extracts are diluted with water until the solution contains about 0., 9 mol / l chloride ions. Then 200 ml of anion exchange cifcjttiLe wo-ti4 CA 9249) in the form of chloride are added and 1.4 are stirred. Then filtered under vacuum and washed with about 200 ml of 0.9 M sodium chloride solution. The ion exchange resin is then stirred for 5 hours with a 2 M solution of sodium chloride at 40 ° C, filtered off with suction and washed with a 2 M solution of sodium chloride. The wash solution is combined with the wash water and precipitated 1.5 times the volume of methanol. The residue is separated in a centrifuge, first washed with about 50 ml of water - methanol (Cl + lf5 vgr), then about 50 MP of methanol and dried. . 198 g of Na-heparinate is obtained from 19505 U-units / mg, 15.5 g of sodium heparinate (200 units of USP / mg), obtained by this method, dissolved in 200 ml of 2 M sodium chloride solution. The solution is sucked off through a suction filter and the residue is washed first with 300 ml of 2 M sodium chloride solution, then about 250 ml of fully demineralized water to the molar content of the chloride ion. 0.9. Repeat cleaning with 1 l lewatit CA 9249; According to the description. . The combined wash out and rinse treatment solution) T according to the described. After washing and drying, the precipitate contains 11.2 g of sodium heparinate, which has an activity of 251 USP-units / mg. Example 10 30 l of brine are diluted with 120 l of water to a molar content of chloride of about 0.85 M, then acidified with acetic acid (about 50 ml) to a pH of 3.2. After a few hours, a residue is precipitated, which is separated by centrifugation after decanting the transparent sludge. After drying, 111 g of crude SPR-U / mg activity of heparin is obtained. An aliquot of the crude heparin thus obtained (respectively, about 425,000 jliSP-u or 65.5 g) is first purified as in Example 1. After the First Purification Stage through an ion exchange resin, 196 g of sodium heparinate is obtained with 198 U. USP / mg. 15 g of sodium heparinate prepared by the method described above, with an activity of about 200 units OSP / mg, are dissolved in 200 ml of a 2 M solution of calcium chloride. The solution is separated by suction filtration and the residue is washed first with 30 ml of 2N. solution of calcium chloride, then about 250 ml of fully demineralized water. The combined solutions are washed with fully demineralized water to a molar chloride content of 0.9. As described, they are mixed with 1 liter of Lewatit SL 9249. The washed out and rinsed solutions are treated instead of a solution of sodium chloride with a solution of 2N. CCE Combined washable and wash solutions are treated as described. After washing and drying the precipitate, 10.7 g of calcium heparinate with an activity of 260 USP-units / mg is obtained. The proposed method allows to increase the purity of the target product, the resulting heparin has a high activity (250-290 IJSPed / mg) compared with the known method (140 -170 USP units / mg), as well as to simplify and reduce the processing of animal raw materials (at low temperatures, the processing time 24 at elevated to b h), in addition, after processing animal raw materials may be suitable for use in the manufacture of sausages.
    权利要求:
    Claims (1)
    [1]
    METHOD FOR PRODUCING HEPARIN · by treating animal raw materials with sodium chloride solution and then isolating it in a known manner, which means that, in order to increase the purity of the target product and simplify the method, intestines freed from mucus are used as raw materials. and the treatment is carried out with solid table salt or its solution in a neutral, medium at 1625 * C.
    类似技术:
    公开号 | 公开日 | 专利标题
    RU2039469C1|1995-07-20|Method for obtaining low-cholesterene egg yolk
    SU1028237A3|1983-07-07|Process for preparing heparin
    JP3371124B2|2003-01-27|Acetyl fucoidan from cultured Okinawa mozuku and its production
    RU1838406C|1993-08-30|Method of preparing of biologically active components
    KR100487994B1|2005-05-09|Process for preparing gelatin from fish
    KR820001739B1|1982-09-27|Process for the recovery of heparin
    FI65073B|1983-11-30|FOERFARANDE FOER FRAMSTAELLNING AV HEPARIN
    US4315923A|1982-02-16|Process for the production of organ extracts with high herparin content
    KR100682646B1|2007-02-15|Purifing method of porphyrans extracted from Porphyra yezoensis using column chromatography
    US3262854A|1966-07-26|Method for the recovery of heparin
    SU654612A1|1979-03-30|Method isolating c cytochrome
    SU442800A1|1974-09-15|The method of obtaining the drug for parenteral protein nutrition
    US2878159A|1959-03-17|Alginic acid purification of insulin
    SU473720A1|1975-06-14|The method of joint production of protamine sulfate and deoxyribonucleic acid
    SU756683A1|1989-11-23|Method of obtaining jellifier from red algae
    SU351545A1|Jaashgno-TNHNk ^; G: 1: D | B * <B; 1IOT1-CL I
    RU2017496C1|1994-08-15|Method of dna sodium salt isolation
    US6316615B1|2001-11-13|Process for the recovery of potassium bitartrate and other products from tamarind pulp
    SU1144700A1|1985-03-15|Method of obtaining protamines
    CN110590940A|2019-12-20|Process for refining SBTI from soybean deep processing waste liquid by ASP dry powder
    SU1027171A1|1983-07-07|Process for preparing pectin
    SU787033A1|1980-12-15|Method of obtaining hemosorbent
    RU2128512C1|1999-04-10|Cytochrome c isolation method
    RU92013657A|1995-10-27|METHOD OF GETTING THE MUGGENTIAL ENZYME
    SU638600A1|1978-12-25|Method of obtaining agaroid
    同族专利:
    公开号 | 公开日
    AU515671B2|1981-04-16|
    FI62104C|1982-11-10|
    GR65226B|1980-07-30|
    IT1088965B|1985-06-10|
    US4283530A|1981-08-11|
    DE2652272B1|1978-05-11|
    ZA776753B|1978-09-27|
    FI62104B|1982-07-30|
    SE432875B|1984-04-30|
    FR2370757A1|1978-06-09|
    YU260677A|1984-10-31|
    BR7707493A|1978-06-20|
    AT354633B|1979-01-25|
    BE860729A|1978-05-10|
    NL179481C|1986-09-16|
    GB1592806A|1981-07-08|
    RO78597A|1982-06-25|
    IL53254D0|1977-12-30|
    HU174644B|1980-02-28|
    NL7711746A|1978-05-17|
    AU3026577A|1979-05-10|
    ATA806677A|1979-06-15|
    DK142059B|1980-08-18|
    DK486177A|1978-05-13|
    FR2370757B1|1982-03-26|
    PL108607B1|1980-04-30|
    BG28425A3|1980-04-15|
    PL202036A1|1978-07-17|
    IS2410A7|1977-12-07|
    NL179481B|1986-04-16|
    LU78488A1|1978-03-14|
    DK142059C|1981-01-19|
    IE772248L|1978-05-12|
    SE7712732L|1978-05-12|
    JPS5362816A|1978-06-05|
    CS208735B2|1981-09-15|
    IL53254A|1980-12-31|
    DD134352A5|1979-02-21|
    DE2652272C2|1979-02-15|
    FI773285A|1978-05-13|
    JPS5844082B2|1983-09-30|
    IE47041B1|1983-12-14|
    CA1088522A|1980-10-28|
    AR214759A1|1979-07-31|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    RU2612813C1|2015-12-07|2017-03-13|Павел Андреевич Канаев|Method of producing heparin|US2623001A|1949-04-07|1952-12-23|Bengt E G V Sylven|Preparing heparin|
    DE1156938B|1957-09-23|1963-11-07|Upjohn Company Eine Ges Nach D|Method for obtaining heparin|
    GB872214A|1957-09-23|1961-07-05|Upjohn Co|Extraction process for the recovery of heparin|
    US3058884A|1959-09-14|1962-10-16|Abbott Lab|Process for purifying heparin|
    NL301375A|1962-12-10|
    US4119774A|1976-03-05|1978-10-10|Ab Kabi|Heparin purification method|DE2800943C2|1978-01-06|1984-09-27|Schering AG, 1000 Berlin und 4709 Bergkamen|Use of intestinal brine to obtain pure heparin|
    HU177887B|1979-03-21|1982-01-28|Richter Gedeon Vegyeszet|Process for preparing a raw material containing heparin|
    AT15142T|1981-05-21|1985-09-15|Akzo Nv|ANTITHROMBOTIC BASED ON POLYSACCHARIDES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAL COMPOSITIONS.|
    WO2016137471A1|2015-02-26|2016-09-01|Nantpharma, Llc|Method for enhanced heparin quality|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    DE2652272A|DE2652272C2|1976-11-12|1976-11-12|Process for the production of heparin|
    [返回顶部]